Moleculin Biotech, Inc.
Data quality: 100%
MBRX
Nasdaq
Manufacturing
Chemicals
$2.54
▲
$0.11
(4.53%)
Mkt Cap: 13.55 M
Price
$2.54
Mkt Cap
13.55 M
Day Range
$2.42 — $2.58
52-Week Range
$1.79 — $28.60
Volume
103,513
Open $2.44
50D / 200D Avg
$3.00
15.43% below
50D / 200D Avg
$8.68
70.74% below
Quick Summary
Key Takeaways
Negative free cash flow of -22.74 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
N/A
ROIC-139.90%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio1.39
Interest CoverageN/A
Valuation
PE (TTM)
-0.40
Above sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.4 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -53.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -33.56 M |
| ROE | N/A | ROA | -160.02% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -22.74 M |
| ROIC | -139.90% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1.39 |
| Interest Coverage | N/A | Asset Turnover | 0.00 |
| Working Capital | 2.20 M | Tangible Book Value | -26.92 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.40 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -167.73% | ||
| Market Cap | 13.55 M | Enterprise Value | 6.85 M |
| Per Share | |||
| EPS (Diluted TTM) | N/A | Revenue / Share | 0.00 |
| FCF / Share | -4.26 | OCF / Share | -4.26 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 67.74% |
| SBC-Adj. FCF | -24.29 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | -33.56 M | -21.76 M | -29.77 M | -29.03 M | -15.89 M |
| EPS (Diluted) | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -25.10 M | -26.64 M | -29.63 M | -30.64 M | -22.97 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 15.89 M | 17.73 M | 19.49 M | 18.97 M | 14.42 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 90,000.0 | 126,000.0 | 127,000.0 | 130,000.0 | 164,000.0 |
| Interest Expense | — | — | — | 240,000.0 | 306,000.0 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 22.13 M | 16.93 M | 38.22 M | 57.42 M | 84.09 M |
| Total Liabilities | 7.12 M | 10.95 M | 12.14 M | 5.23 M | 5.10 M |
| Shareholders' Equity | 15.01 M | 5.98 M | 26.07 M | 52.19 M | 78.99 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 8.88 M | 4.28 M | 23.55 M | 43.15 M | 70.90 M |
| Current Assets | 9.69 M | 5.19 M | 26.27 M | 45.60 M | 72.50 M |
| Current Liabilities | 6.85 M | 5.36 M | 6.82 M | 4.82 M | 3.62 M |
{"event":"ticker_viewed","properties":{"ticker":"MBRX","listing_kind":"stock","pathname":"/stocks/mbrx","exchange":"Nasdaq","country":"US"}}